Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

USAEquityResearch Aug. 24 at 11:23 PM

$DCTH 📊 USAEquityResearch ▼ 16.75 (-2.28%) Trend: Bullish 📈 RSI (14): 70.5 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 17.36 | Support: 11.55 20-MA: 15.18 | 50-MA: 13.62 💼 Fundamentals Mkt Cap: $581.20M P/E (TTM): 1675.0 | Fwd P/E: 372.2 FCF: $18.12M (0.52/sh) Total Debt: $2.46M D/E: 2.03 📉 Options (exp 2026-09-18) ATM IV: 59.6% | Skew: -2.9% (call-heavy) P/C Ratio: 0.01 🐂 Bullish lean Max Pain: 10.00 Call wall: 17.50 | Put wall: 15.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/DCTH

0 · Reply

USAEquityResearch Aug. 22 at 12:33 AM

$DCTH 📊 USAEquityResearch ▲ 17.14 (+2.33%) Trend: Bullish 📈 RSI (14): 74.1 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 17.36 | Support: 11.55 20-MA: 14.94 | 50-MA: 13.52 💼 Fundamentals Mkt Cap: $594.74M P/E (TTM): 1714.0 | Fwd P/E: 380.9 FCF: $18.12M (0.52/sh) Total Debt: $2.46M D/E: 2.03 📉 Options (exp 2026-09-18) ATM IV: 50.7% | Skew: +65.1% (put-heavy) P/C Ratio: 0.02 🐂 Bullish lean Max Pain: 10.00 Call wall: 17.50 | Put wall: 15.00 Educational content only. Not financial advice.

0 · Reply

Humdinger1966 Aug. 21 at 4:10 PM

$DCTH I see MRNA nd Merck had huge trial success this week. MRNA has a melanoma vaxx that works well in cutaneous melanoma. Merck and MRNA collaborated to run a joint trial of Keytruda + Vaxx in order to explore the synergy between the two. It seems to me that a Keytruda + Hepzato trial for any liver mets cancer has to be a no brainer for the very same reason. If Merck does not get Keytruda involved then its rival drug Opdivo (Nivo) will own the CHOPIN protocol approach to liver mets. Why has Merck not jumped at this?

0 · Reply

brunoq14 Aug. 18 at 2:47 PM

$DCTH IMCR is getting a lot of love recently. Jefferies initiated with a $48 target price, and Wainwright reiterated $100.

1 · Reply

brunoq14 Aug. 17 at 3:02 PM

$DCTH According to Schwab, institutional ownership is now up to 49.75%.

0 · Reply

Humdinger1966 Aug. 16 at 3:56 PM

$DCTH From latest DCTH corporate presentation: "Repurchase of 0.9M shares to date under Share Buyback program". But, we know they spent $9M (Q2 earnings call), so they got them at 10 bucks a share. Nice!

1 · Reply

xcdvfxcvnbxxvsd Aug. 16 at 1:30 PM

$DCTH preparing to manufacture and store all those kits after breast and col approvals :) https://www.bizjournals.com/albany/news/2026/08/09/delcath-kingsbury-hq-expansion.html?csrc=6398&taid=6a7d922b8c81560001572bfb&utm_campaign=trueanthem&utm_medium=social&utm_source=twitter

1 · Reply

alexpitti Aug. 14 at 9:13 PM

i bought $ABVX sold $MIST i lost money on $ABEO and $STXS i made money?????? on $DCTH

2 · Reply

focafoca99 Aug. 14 at 12:33 PM

$DCTH amended its bylaws, setting Delaware Chancery as exclusive forum for internal claims and federal courts for securities claims. https://www.rapidticker.com/news/dcth-sec-filing-147d6d

0 · Reply

Zephix Aug. 13 at 9:13 PM

$DCTH $WWR chocklate

0 · Reply

Delcath Systems price target raised to $32 from $30 at H.C. Wainwright

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Delcath Systems Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Delcath Systems Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Delcath Systems Quarterly report: Q2 2026

2026-08-06T12:17:47.000Z - 18 days ago

Delcath Systems reports Q2 EPS 7c, consensus (9c)

2026-08-06T12:16:56.000Z - 18 days ago

Delcath Systems sees positive adjusted EBITDA in FY26

Aug 6, 2026, 8:01 AM EDT - 18 days ago

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Jul 28, 2026, 4:01 PM EDT - 27 days ago

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

Jul 23, 2026, 4:01 PM EDT - 4 weeks ago

Delcath Systems to Host Second Quarter 2026 Earnings Call

Jul 16, 2026, 4:01 PM EDT - 5 weeks ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-13T11:20:52.000Z - 6 weeks ago

Delcath Systems price target raised to $17 from $16 at BTIG

2026-07-09T12:05:51.000Z - 6 weeks ago

Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer

Jul 9, 2026, 8:00 AM EDT - 6 weeks ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

2026-05-26T20:05:59.000Z - 3 months ago

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

May 26, 2026, 4:01 PM EDT - 3 months ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 12, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-07T14:11:04.000Z - 3 months ago

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T13:35:47.000Z - 3 months ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:34:32.000Z - 3 months ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Apr 23, 2026, 8:30 AM EDT - 4 months ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 6, 2026, 8:30 AM EDT - 5 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

2026-04-02T14:44:15.000Z - 5 months ago

Delcath Systems management to meet with Craig Hallum

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

2026-03-03T13:43:26.000Z - 6 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 6 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

2026-02-26T18:26:15.000Z - 6 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T13:33:50.000Z - 6 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:07.000Z - 6 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Feb 26, 2026, 8:30 AM EST - 6 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 6 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 7 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-09T15:30:16.000Z - 8 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T13:15:29.000Z - 8 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Jan 9, 2026, 8:05 AM EST - 8 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

2025-12-31T13:15:08.000Z - 8 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Dec 31, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

2025-12-03T21:05:29.000Z - 9 months ago

Delcath Systems announces publication of CHEMOSAT study

Dec 3, 2025, 4:01 PM EST - 9 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Nov 20, 2025, 4:01 PM EST - 9 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 18, 2025, 8:00 AM EST - 9 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 13, 2025, 8:30 AM EST - 10 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 10 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:30 AM EST - 10 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 20, 2025, 8:45 AM EDT - 11 months ago

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 11 months ago

Delcath Systems Press release: Study Result

Oct 20, 2025, 7:00 AM EDT - 11 months ago

Delcath Systems Slides: Corporate Presentation

Oct 18, 2025, 4:15 PM EDT - 11 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 11 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 10, 2025, 11:00 AM EDT - 1 year ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

USAEquityResearch Aug. 24 at 11:23 PM

0 · Reply

USAEquityResearch Aug. 22 at 12:33 AM

0 · Reply

Humdinger1966 Aug. 21 at 4:10 PM

0 · Reply

brunoq14 Aug. 18 at 2:47 PM

$DCTH IMCR is getting a lot of love recently. Jefferies initiated with a $48 target price, and Wainwright reiterated $100.

1 · Reply

brunoq14 Aug. 17 at 3:02 PM

$DCTH According to Schwab, institutional ownership is now up to 49.75%.

0 · Reply

Humdinger1966 Aug. 16 at 3:56 PM

1 · Reply

xcdvfxcvnbxxvsd Aug. 16 at 1:30 PM

1 · Reply

alexpitti Aug. 14 at 9:13 PM

i bought $ABVX sold $MIST i lost money on $ABEO and $STXS i made money?????? on $DCTH

2 · Reply

focafoca99 Aug. 14 at 12:33 PM

$DCTH amended its bylaws, setting Delaware Chancery as exclusive forum for internal claims and federal courts for securities claims. https://www.rapidticker.com/news/dcth-sec-filing-147d6d

0 · Reply

Zephix Aug. 13 at 9:13 PM

$DCTH $WWR chocklate

0 · Reply

brunoq14 Aug. 12 at 10:28 PM

$DCTH The revenue targets on Yahoo Finance now are lower than they were for Q2.

0 · Reply

efficiency Aug. 12 at 3:58 PM

$DCTH Trend measures 62% in 200 days. Lots of room UP. Add a tranche above 18 and 20 is a potent round number.

0 · Reply

actuallysam Aug. 12 at 1:43 PM

$DCTH I have been vast majority of time in delcath since 2003 but heavier position over last 2 years than ever before. That is why Polaris is so right because virtually all the previous running the company were just terrible in great contrast. It is a good reason to believe there is probably 70 to 75 percent chance that phase 2 colorectal will be good. I will guess 30 to 35 percent chance of buyout before phase 2 read out, but I suspect no earlier than late May of 2027 for a buyout.

0 · Reply

Polaris2024 Aug. 12 at 11:35 AM

$DCTH MR22, I have played with stocks for 57 years and of all the CEO’s I have studied I think Gerrard is number one in my books. He supports the stock financially personally when needed, never over estimates predictions and always a straight shooter if there is a crisis and explains this to analysts in a way that clears the situation. I think that is why I have such a conviction for this company. I have always take large position in a few stocks and this one I have probably 50% of my assets after this latest run.

1 · Reply

brunoq14 Aug. 12 at 1:06 AM

$DCTH 17.42 new 52 week high.

1 · Reply

mar99 Aug. 11 at 4:08 PM

$DCTH Hard to believe just 9 months ago we were under a selling assault about to go below 8 when the company took the amazing step for a stock like this and announced the share buyback plus Gerard buying shares to stop the bleeding. Here we are 9 months later at 17 with the company seemingly clicking on all cylinders and future looks very bright. The algos, bots, shorts and manipulators no longer seem to have their foot on our throat. Stock goes up and isn’t immediately getting taken back down. Quite a nice change. Sure feels good. Kudos to Gerard for doing a great job.

1 · Reply

Playthegame06 Aug. 11 at 2:50 PM

$DCTH Q: Where is FAIR VALUE??? Where will this run end???

1 · Reply

alexpitti Aug. 11 at 2:19 PM

$DCTH bro thinks this is a casino

1 · Reply

boohoooomillenials Aug. 11 at 2:17 PM

$DCTH now at 59% probably going to trim half now and play with house money

0 · Reply

Playthegame06 Aug. 11 at 2:02 PM

$DCTH another 52 Week high but I doubt we will achieve the ALL TIME HIGH😃

1 · Reply

Playthegame06 Aug. 11 at 2:00 PM

$DCTH More centers means more revenues and with a low float that means higher stock price. And I believe $30 is within reach before Phase 2 Readout in late 2027.

0 · Reply

actuallysam Aug. 11 at 1:27 PM

$DCTH i think cutaneous would be interesting, hard to predict all the action over next 12 to 18 months, but I do not think $30 will be reached before a phase 2 readout unless there is a buyout which could push close to $40

0 · Reply

Market Cap	594.74M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	1,675.00
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	417,000
Avg Vol	556,876
Day's Range	N/A - N/A
Shares Out	34.70M
Stochastic %K	27%
Beta	0.52
Analysts	Strong Sell
Price Target	$25.00